insights_auto
Outlook: 93.3% bullish·0.0% bearish
Go to analysischevron_right
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$123.11
arrow_upward
+1.04%(+1.27) 1D
Oct 19, 1:19:17 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$121.72
High
$123.51
Low
$121.68
Mkt. cap
13.97B
Avg. vol.
2.43M
Volume
534.30K
P/E ratio
36.78
52-wk high
$123.51
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
Open
$121.72
High
$123.51
Low
$121.68
Mkt. cap
13.97B
Avg. vol.
2.43M
Volume
534.30K
P/E ratio
36.78
52-wk high
$123.51
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
Zacks
·
4 hours ago
Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron
Zacks
·
4 hours ago
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics
StockStory
·
1 day ago
2 Reasons to Like HALO (and 1 Not So Much)
Investing.com
·
3 days ago
H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com